Abcam and Transinsight Collaborate in the Area of Semantic Search Technologies

Abcam, a bioscience company specialising in the supply of antibodies from a web-based catalogue and Transinsight, a specialist in semantic search technologies announced a collaboration in the field of protein information quality control using bioinformatics workflows.

Accurately compiling all the required information around antibody targets is a challenging task, which has created the requirement for an automated intelligent computer-based solution to ensure top-quality information content about proteins. For example, an average human gene name has 6 or 7 synonyms and many more spelling variants. Hand-curated databases do not cover all possible ways of naming and spelling genes and hand-curation is a tedious, error prone and labour-intensive task.

"Until recently there were only limited software tools and scientific workflows available to help us automatically produce high quality data sets surrounding each of Abcam’s thousands of antibody targets. We need these data sets to help our customers find the right products", says Dr. Harter, Senior Business Development Manager at Abcam. Harter continues "We were looking for solutions for supporting our team of experts and were impressed by the advanced technologies of Transinsight. The fact that the company operates the semantic search engine GoPubMed.org and has extensive bioinformatics and protein databases expertise made the decision to work with Transinsight easy."

The award winning technology behind GoPubMed fully automates very difficult analyses normally done by scientists with equal or better performance, predicting the necessary information by sophisticated algorithms. "It is good to see how we can significantly enhance our customers' performance by improving their data quality and thus freeing their staff from an unnecessary burden" says Michael R. Alvers, CEO at Transinsight.

About Abcam
Abcam plc is a producer and distributor of research-grade antibodies and associated products headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japan office located in Tokyo. The Company produces and distributes its own and third party produced antibodies to academic and commercial customers throughout the world with product information and ordering available through the Company’s website, www.abcam.com. Abcam’s vision is to build the largest online catalogue of the best antibodies in the world.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honoured with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, Abcam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

Most Popular Now

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

Abbott launches new initiative to drive diversity …

Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, ed...

Needle-free COVID-19 vaccine shows promise

A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed...

Cleveland Clinic launches first-of-its kind preven…

Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of ...

Novartis to sell its Roche stake in a bilateral tr…

Novartis has agreed to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion. Vas...